B cell

(redirected from B-cells)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Related to B-cells: Plasma B cells
  • noun

Synonyms for B cell

a lymphocyte derived from bone marrow that provides humoral immunity

References in periodicals archive ?
In addition to presenting antigen, B-cells may also influence the immune response through expression of distinct profiles of accessory molecules and/or production of an array of effector cytokines.
In a pre-clinical study, ofatumumab appeared to be more effective than rituximab in treating chemotherapy refractory diffuse large B-cell lymphoma (DLBCL).
ZEVALIN is approved in Europe for the treatment of adult patients with CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL) who are refractory to or have relapsed following RITUXAN (rituximab) therapy.
While eliminating a major class of immune cells sounds drastic, scientists have unexpectedly found that B-cell depletion doesn't leave the human body vulnerable to infectious disease.
After a single dose to wipe out all the patient's B-cells the body responds by making new ones - and the chances of them making the same mistake is tiny.
B-cells usually regenerate after Rituxan treatment and return to normal levels in about 12 months for most patients.
As a result of these complex hormonal changes, B-cells of pancreas begin to manufacture insulin efficiently, after bariatric surgery.
We took normal B-cells from mice, and sprinkled GIFT15 on them, which led to this Jekyll and Hyde effect.
GlaxoSmithKline (GSK) and Genmab A/S (CSE: GEN) today announced a worldwide agreement to co-develop and commercialize HuMax-CD20(TM) (ofatumumab), a fully human monoclonal antibody in late stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin's lymphoma (NHL) and in Phase II for rheumatoid arthritis (RA).
It "targets and selectively depletes CD20-positive B-cells, without targeting stem cells or existing plasma cells," according to Genentech Inc.
B-cells that have expressed a ligand to receptor protein H4-1BB can be treated with cells that have expressed receptor protein H4-1BB and B-cell proliferation may be induced.
It focuses on the so-called B-cells, white blood cells that defend the body against viruses.
This interleukin regulates B-cells and also stimulates the growth of T-cells.
Stem cells (B-cell progenitors that give rise to B-cells) in bone marrow do not have the CD20 protein allowing B-cells to repopulate after Rituxan treatment.
It is not clear whether it will be desirable to produce only islet b-cells that manufacture insulin or whether other types of pancreatic islet cells are also necessary.